A Single-Dose Clinical Trial to Study the Safety, Tolerability, Pharmacokinetics, and Anti-Retroviral Activity of MK-8527 Monotherapy in Anti-Retroviral Therapy (ART)-Naïve, HIV-1 Infected Participants
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 14 Feb 2019
At a glance
- Drugs MK-8527 (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 05 Feb 2019 Planned initiation date changed from 8 Feb 2019 to 11 Feb 2019.
- 16 Jan 2019 Planned initiation date changed from 11 Jan 2019 to 8 Feb 2019.
- 13 Dec 2018 Planned initiation date changed from 7 Dec 2018 to 11 Jan 2019.